Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 41 Stomach Neoplasms 9 Neoplasm Metastasis 7 Esophageal Neoplasms 7 Colorectal Neoplasms 6 Neoplasms 5 HER2-positive Breast Cancer 5 Endometrial Neoplasms 4 Triple Negative Breast Neoplasms 3 Rectal Neoplasms 3 Ovarian Neoplasms 3 Multiple Myeloma 3 Lung Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Adenocarcinoma Of Esophagus 3 Adenocarcinoma 3 Squamous Cell Carcinoma of Head and Neck 2 Solid Tumors 2 Salivary Gland Neoplasms 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Lymphoma, Non-Hodgkin 2 Colonic Neoplasms 2 Brain Neoplasms 2 Biliary Tract Neoplasms 2 Anatomic Stage II Breast Cancer AJCC v8 2 Anatomic Stage I Breast Cancer AJCC v8 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1

Interventions

pertuzumab 1 Trastuzumab 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced HER2+Breast Cancer × Trastuzumab × 90 days × Clear all

NCT04208178 2026-04-02

EPIK-B2

Novartis

Phase 3 Active not recruiting

Advanced HER2+Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡